Dendritic cell subsets in type 1 diabetes: friend or foe?

Type 1 diabetes (T1D) is a T cell mediated autoimmune disease characterized by immune mediated destruction of the insulin producing β cells in the islets of Langerhans. Dendritic cells (DC) have been implicated in the pathogenesis of T1D and are also used as immunotherapeutic agents. Plasmacytoid (p...

Full description

Bibliographic Details
Main Author: Penelope Anne Morel
Format: Article
Language:English
Published: Frontiers Media S.A. 2013-12-01
Series:Frontiers in Immunology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fimmu.2013.00415/full
id doaj-bc82c4d0d479496ba395ca55b246d6b4
record_format Article
spelling doaj-bc82c4d0d479496ba395ca55b246d6b42020-11-24T22:57:08ZengFrontiers Media S.A.Frontiers in Immunology1664-32242013-12-01410.3389/fimmu.2013.0041571010Dendritic cell subsets in type 1 diabetes: friend or foe?Penelope Anne Morel0University of PittsburghType 1 diabetes (T1D) is a T cell mediated autoimmune disease characterized by immune mediated destruction of the insulin producing β cells in the islets of Langerhans. Dendritic cells (DC) have been implicated in the pathogenesis of T1D and are also used as immunotherapeutic agents. Plasmacytoid (p)DC have been shown to have both protective and pathogenic effects and a newly described merocytic DC population has been shown to break tolerance in the mouse model of T1D, the non obese diabetic (NOD) mouse. We have used DC populations to prevent the onset of T1D in NOD mice and clinical trials of DC therapy in T1D diabetes have been initiated. In this review we will critically examine the recent published literature on the role of DC subsets in the induction and regulation of the autoimmune response in T1D.http://journal.frontiersin.org/Journal/10.3389/fimmu.2013.00415/fullAutoimmunityDendritic CellstolerancetherapyT regulatory cellstype 1 diabetes
collection DOAJ
language English
format Article
sources DOAJ
author Penelope Anne Morel
spellingShingle Penelope Anne Morel
Dendritic cell subsets in type 1 diabetes: friend or foe?
Frontiers in Immunology
Autoimmunity
Dendritic Cells
tolerance
therapy
T regulatory cells
type 1 diabetes
author_facet Penelope Anne Morel
author_sort Penelope Anne Morel
title Dendritic cell subsets in type 1 diabetes: friend or foe?
title_short Dendritic cell subsets in type 1 diabetes: friend or foe?
title_full Dendritic cell subsets in type 1 diabetes: friend or foe?
title_fullStr Dendritic cell subsets in type 1 diabetes: friend or foe?
title_full_unstemmed Dendritic cell subsets in type 1 diabetes: friend or foe?
title_sort dendritic cell subsets in type 1 diabetes: friend or foe?
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2013-12-01
description Type 1 diabetes (T1D) is a T cell mediated autoimmune disease characterized by immune mediated destruction of the insulin producing β cells in the islets of Langerhans. Dendritic cells (DC) have been implicated in the pathogenesis of T1D and are also used as immunotherapeutic agents. Plasmacytoid (p)DC have been shown to have both protective and pathogenic effects and a newly described merocytic DC population has been shown to break tolerance in the mouse model of T1D, the non obese diabetic (NOD) mouse. We have used DC populations to prevent the onset of T1D in NOD mice and clinical trials of DC therapy in T1D diabetes have been initiated. In this review we will critically examine the recent published literature on the role of DC subsets in the induction and regulation of the autoimmune response in T1D.
topic Autoimmunity
Dendritic Cells
tolerance
therapy
T regulatory cells
type 1 diabetes
url http://journal.frontiersin.org/Journal/10.3389/fimmu.2013.00415/full
work_keys_str_mv AT penelopeannemorel dendriticcellsubsetsintype1diabetesfriendorfoe
_version_ 1725651836369633280